Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
OtherClinical Investigations

Prognostic Value of PET Using 18F-FDG in Hodgkin’s Disease for Posttreatment Evaluation

Christian Guay, Mariette Lépine, Jean Verreault and François Bénard
Journal of Nuclear Medicine August 2003, 44 (8) 1225-1231;
Christian Guay
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mariette Lépine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean Verreault
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
François Bénard
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • FIGURE 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 1.

    Kaplan–Meier estimate of disease-free interval in 36 patients with negative 18F-FDG PET and 12 patients with positive 18F-FDG PET. Time intervals are in days.

  • FIGURE 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 2.

    Kaplan–Meier estimate of disease-free interval. 18F-FDG PET was performed in first 30 d after chemotherapy (A) and 91–365 d after chemotherapy (B). Time intervals are in days.

  • FIGURE 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 3.

    Kaplan–Meier estimate of disease-free interval in patients with positive CT or 18F-FDG PET studies. In patients with either negative CT or PET study, survival curves were almost identical and showed very low rate of relapse. Time intervals are in days.

Tables

  • Figures
    • View popup
    TABLE 1

    Patient Characteristics

    CharacteristicNo. of patients
    Total no. of cases48
     Males24
     Females24
    Age (y)
     Median38
     Range17–78
    Ann Arbor clinical stage
     I2
     II23
     III15
     IV8
    Treatment
     Chemotherapy alone17
     Chemotherapy and radiotherapy31
     No. of cycles (mean)7
    Time interval between end of chemotherapy and PET (d)
     Median58
     Range0–1,639
    Follow-up duration from end of chemotherapy (d)
     Median486
     Range15–1,861
    Follow-up duration after PET (d)
     Median210
     Range1–875
    • View popup
    TABLE 2

    Relationships Between PET Scan Results, Clinical Outcome, and Predictive Values

    Time between PET scan and last cycle of chemotherapy (d)18F-FDG PETRelapsePredictive values (%)
    PositiveNegative
    0–30Positive (n = 6)60100
    Negative (n = 8)2675
    31–90Positive (n = 1)10100
    Negative (n = 12)11192
    91–365Positive (n = 5)4180
    Negative (n = 8)08100
    >365Positive (n = 0)00NA*
    Negative (n = 8)08100
    • ↵* No patients in this subgroup.

    • View popup
    TABLE 3

    Comparison Between 18F-FDG PET and CT

    ImagingNo.True +True −False +False −Sensitivity (%)Specificity (%)PPV (%)NPV (%)Accuracy (%)
    PET4811331379*97†92‡92*92†
    CT3210812283*40†45‡80*56†
    • ↵* No statistical difference.

    • ↵† P < 0.0005.

    • ↵‡ P < 0.05.

    • PPV = positive predictive value; NPV = negative predictive value.

      Comparison was for 32 patients with available CT scans.

PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 44, Issue 8
August 1, 2003
  • Table of Contents
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Prognostic Value of PET Using 18F-FDG in Hodgkin’s Disease for Posttreatment Evaluation
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Prognostic Value of PET Using 18F-FDG in Hodgkin’s Disease for Posttreatment Evaluation
Christian Guay, Mariette Lépine, Jean Verreault, François Bénard
Journal of Nuclear Medicine Aug 2003, 44 (8) 1225-1231;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Prognostic Value of PET Using 18F-FDG in Hodgkin’s Disease for Posttreatment Evaluation
Christian Guay, Mariette Lépine, Jean Verreault, François Bénard
Journal of Nuclear Medicine Aug 2003, 44 (8) 1225-1231;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • Acknowledgments
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology
  • Hodgkin Lymphoma, Version 2.2015
  • The Role of PET and PET/CT in Managing the Care of Lymphoma Patients
  • Hodgkin Lymphoma
  • PET/CT for Therapy Response Assessment in Lymphoma
  • Role of PET/CT Scanning in Initial and Post-Treatment Assessment of Hodgkin Disease
  • 18F-FDG PET for Posttherapy Assessment of Hodgkin's Disease and Aggressive Non-Hodgkin's Lymphoma: A Systematic Review
  • Early 18F-FDG PET for Prediction of Prognosis in Patients with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment Versus Visual Analysis
  • Impact of Positive Positron Emission Tomography on Prediction of Freedom From Progression After Stanford V Chemotherapy in Hodgkin's Disease
  • Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome
  • 18F-FDG PET for Evaluation of the Treatment Response in Patients with Gastrointestinal Tract Lymphomas
  • Current Concepts in Lymph Node Imaging
  • Hodgkin's Lymphoma: Evolving Concepts with Implications for Practice
  • Google Scholar

More in this TOC Section

  • Feasibility of Ultra-Low-Activity 18F-FDG PET/CT Imaging Using a Long–Axial-Field-of-View PET/CT System
  • Cardiac Presynaptic Sympathetic Nervous Function Evaluated by Cardiac PET in Patients with Chronotropic Incompetence Without Heart Failure
  • Validation and Evaluation of a Vendor-Provided Head Motion Correction Algorithm on the uMI Panorama PET/CT System
Show more Clinical Investigations

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire